Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methylergometrine (also known as methylergonovine) is a semi-synthetic ergot alkaloid used primarily in obstetrics to prevent or treat postpartum hemorrhage and uterine atony. It acts as a potent uterotonic by directly stimulating the smooth muscle of the uterus, increasing tone, rate, and amplitude of contractions, thereby reducing blood loss after childbirth or abortion. It is also sometimes used for the prevention and acute treatment of migraine headaches. The drug can be administered orally, intramuscularly, or intravenously. At high doses it may produce psychedelic effects similar to LSD due to its structural similarity as an ergoline derivative[1][2][5]. Methylergometrine is on the World Health Organization's List of Essential Medicines[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylergometrine.